Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Mirum Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 6 Next >
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Tickers MIRM
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.